Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and LivaNova (LIVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT) and LivaNova (LIVN).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics (SRPT)
Needham analyst Gil Blum maintained a Sell rating on Sarepta Therapeutics today. The company’s shares closed last Thursday at $17.06.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $21.28 average price target, which is a 25.6% upside from current levels. In a report issued on March 10, Citi also maintained a Sell rating on the stock with a $9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
LivaNova (LIVN)
Needham analyst Michael Matson maintained a Buy rating on LivaNova today and set a price target of $81.00. The company’s shares closed last Thursday at $63.22, close to its 52-week high of $64.48.
According to TipRanks.com, Matson is a 1-star analyst with an average return of
LivaNova has an analyst consensus of Strong Buy, with a price target consensus of $80.13, representing a 26.8% upside. In a report issued on March 11, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $69.00 price target.
Read More on SRPT:
Disclaimer & DisclosureReport an Issue
- Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer
- Sarepta provides regulatory update on Amondys 45, Vyondys 53
- Sarepta begins screening, enrollment in Cohort 8 of ENDEAVOR study
- Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
- Sarepta price target raised to $31 from $26 at Mizuho
